| DC46238 |
MC-Val-Cit-PAB-dimethylDNA31 |
MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus. |
|
| DC46251 |
Azide-PEG4-VC-PAB-Doxorubicin |
Azide-PEG4-VC-PAB-Doxorubicin is a drug-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody drug conjugate (ADC). |
|
| DC46259 |
MRTX849 ethoxypropanoic acid |
MRTX849 ethoxypropanoic acid incorporates a ligand for KRAS G12C, and a PROTAC linker. MRTX849 ethoxypropanoic acid can be used in the synthesis of PROTAC LC-2. LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50s between 0.25 and 0.76 μM).
|
|
| DC46277 |
K-Ras ligand-Linker Conjugate 2 |
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1, which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells. |
|
| DC46407 |
Desmethyl Vc-seco-DUBA |
Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC46408 |
Gly3-VC-PAB-MMAE
Featured
|
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC57082 |
MC-MMAE
Featured
|
Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC. |
|
| DC47148 |
Mal-(CH2)5-Val-Cit-PAB-Eribulin |
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB. |
|
| DC47680 |
PSMA-Val-Cit-PAB-MMAE
Featured
|
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer. |
|
| DC47681 |
PNU-EDA-Gly5 |
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5. |
|
| DC48008 |
DGN549-L |
DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC48384 |
Mal-amido-PEG8-Val-Ala-PAB-SG3200 |
Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a site-specific antibody-drug conjugate (extracted from patent WO2016166300A1). |
|
| DC48385 |
MC-VC-PABC-amide-PEG1-CH2-CC-885 |
MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugates (ADC) based on protein degrading agent (protac molecular glue, etc.). |
|
| DC48400 |
Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan |
Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugate used to synthesis ADC. Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan comprises topoisomerase inhibitor derivative with a linker for connecting to a ligand unit (extracted from patent US20200306243A1). |
|
| DC50212 |
CL2E-SN38 |
CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor. |
|
| DC50213 |
Aminooxy CatB-LXR |
Aminooxy CatB-LXR (compound 10) is a drug-linker conjugates for ADC. |
|
| DC50214 |
MC-Val-Cit-PAB-DX8951 |
MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker.
|
|
| DC50215 |
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT |
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT has the potential for cancer and autoimmune disease research. |
|
| DC50216 |
CL2E-SN38 TFA |
CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor. |
|
| DC71115 |
SN38 NHS ester
Featured
|
SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs). |
|
| DC71150 |
Aminobenzenesulfonic auristatin E |
Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
|
| DC71664 |
Val-Cit-PAB-MMAF sodium
Featured
|
Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
|
|
| DC71665 |
Val-Cit-PAB-MMAF
Featured
|
Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
|
|
| DC71666 |
MC-VA-PABC-MMAE |
MC-VA-PABC-MMAE is a drug-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE. |
|
| DC71667 |
Aminobenzenesulfonic auristatin E TFA |
Aminobenzenesulfonic auristatin E TFA is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
|
| DC80073 |
Azido-PEG4-EV-Cit-PAB-MMAE
Featured
|
Azido-PEG4-EV-Cit-PAB-MMAE is a precursor of antibody drug conjugate. |
|
| DC71949 |
MC-VA-PAB-Exatecan |
MC-VA-PAB-Exatecan is a drug-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan. MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity. |
|
| DC71950 |
Ac-Lys-Val-Cit-PABC-MMAE
Featured
|
Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE. |
|
| DC71951 |
Aminobenzenesulfonic auristatin E-d8 |
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
|
| DC72119 |
Deruxtecan analog 2 |
Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
|
|
